Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND PURPOSE: It is proposed that isocitrate dehydrogenase 1 (IDH1) mutation predicts the outcome in patients with high-grade glioma. In addition, contrast enhancement on preoperative MR imaging reflects tumor biologic features. Patients with anaplastic glioma with the IDH1 mutation were evaluated by using MR imaging to determine whether tumor enhancement is a prognostic factor and can be used to predict survival. MATERIALS AND METHODS: A cohort of 216 patients with histologically confirmed anaplastic glioma was reviewed retrospectively. Tumor contrast-enhancement patterns were classified on the basis of preoperative T1 contrast MR images. Tumor IDH1 status was examined by using RNA sequencing. We used univariate analysis and the multivariate Cox model to evaluate the prognostic value of the IDH1 mutation and tumor contrast-enhancement pattern for progression-free survival and overall survival. RESULTS: In all 216 patients, IDH1 mutation was associated with longer progression-free survival (P = .004, hazard ratio = 0.439) and overall survival (P = .002, hazard ratio = 0.406). For patients with IDH1 mutant anaplastic glioma, the absence of contrast enhancement was associated with longer progression-free survival (P = .038, hazard ratio = 0.473) and overall survival (P = .043, hazard ratio = 0.436). Furthermore, we were able to stratify the progression-free survival and overall survival of patients with IDH1 mutation by using the tumor contrast-enhancement patterns (P = .022 and 0.029, respectively; log-rank). CONCLUSIONS: Tumor enhancement on postcontrast MR imaging is a valuable prognostic factor for patients with anaplastic glioma and IDH1 mutation. Furthermore, the contrast-enhancement patterns could potentially be used to stratify the survival outcome of such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036 · cited 1×
“with low-grade glioma is generally better than that of patients with glioblastoma.(1,14,15,22) This variance of IDH1 mutation inci-”
BackgroundBeiko, J., Suki, D., Hess, K. R., Fox, B. D., Cheung, V., Cabral, M., Shonka, N., Gilbert, M. R., Sawaya, R., Prabhu, S. S., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not159 · Cited by 456
Cited by
Nie, D., Lu, J., Zhang, H., Adeli, E., Wang, J., Yu, Z., Liu, L., Wang, Q., Wu, J., & Shen, D. (2019) · Scientific Reports · doi:10.1038/s41598-018-37387-9 · Cited by 213
Self-citationvan den Bent, M. J., French, P. J., Brat, D., Tonn, J. C., Touat, M., Ellingson, B. M., Young, R. J., Pallud, J., von Deimling, A., Sahm, F., et al. (2024) · Neuro-Oncology · doi:10.1093/neuonc/noae107 · Cited by 88
Suchorska, B., Schüller, U., Biczok, A., Lenski, M., Albert, N. L., Giese, A., Kreth, F.-W., Ertl-Wagner, B., Tonn, J.-C., & Ingrisch, M. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.019 · Cited by 59
Metadata
- Authors
- Wang, Y. Y., Wang, K., Li, S. W., Wang, J. F., Ma, J., Jiang, T., & Dai, J. P.
- Venue
- American Journal of Neuroradiology
- Published
- 2015-08-27
- Volume
- 36
- Issue
- 11
- Pages
- 2023-2029
- ISSN
- 0195-6108 (ISSN-L)
- 1936-959X
- OpenAlex
- W2179124818
- Cited by
- 56
- References
- 2
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation. https://app.cochat.ai/papers/10.3174/ajnr.a4407
- The paper
- Wang, Y. Y., Wang, K., Li, S. W., Wang, J. F., Ma, J., Jiang, T., & Dai, J. P. (2015). Patterns of Tumor Contrast Enhancement Predict the Prognosis of Anaplastic Gliomas with IDH1 Mutation. American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.a4407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.